These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26089640)

  • 41. Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer.
    Yang B; Kou R; Wang H; Wang A; Wang L; Sun S; Shi M; Zhao S; Wang Y; Wang Y; Wu J; Wu F; Yang F; Qu M; Yu W; Gao Z
    Int J Mol Med; 2024 Aug; 54(2):. PubMed ID: 38963035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer.
    Fishel ML; Xia H; McGeown J; McIlwain DW; Elbanna M; Craft AA; Kaimakliotis HZ; Sandusky GE; Zhang C; Pili R; Kelley MR; Jerde TJ
    Mol Cancer Ther; 2019 Nov; 18(11):1947-1960. PubMed ID: 31413178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
    Maj E; Filip-Psurska B; Milczarek M; Psurski M; Kutner A; Wietrzyk J
    Int J Oncol; 2018 Feb; 52(2):337-366. PubMed ID: 29345296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
    Han L; Wang JN; Cao XQ; Sun CX; Du X
    Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
    Coxon A; Ziegler B; Kaufman S; Xu M; Wang H; Weishuhn D; Schmidt J; Sweet H; Starnes C; Saffran D; Polverino A
    Mol Cancer; 2012 Sep; 11():70. PubMed ID: 22992329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
    Wang Y; Wang X; Xu G; Gou S
    J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
    Pan C; Duan H; Wu Y; Zhu C; Yi C; Duan Y; Lu D; Guo C; Wu D; Wang Y; Fu X; Xu J; Chen Y; Luo M; Tian W; Pan T; Xu W; Zhang S; Huang J
    Int J Oncol; 2020 Oct; 57(4):939-955. PubMed ID: 32945394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft.
    Jia Y; Zhou D; Jia Q; Ying Y; Chen S
    Biomed Pharmacother; 2016 Apr; 79():27-34. PubMed ID: 27044809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.
    Tian H; Liu S; Zhang J; Zhang S; Cheng L; Li C; Zhang X; Dail L; Fan P; Dai L; Yan N; Wang R; Wei Y; Deng H
    J Biomed Nanotechnol; 2012 Aug; 8(4):633-41. PubMed ID: 22852473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells.
    Lee JH; Chung KS; Lee HH; Ko D; Kang M; Yoo H; Ahn J; Lee JY; Lee KT
    Biomed Pharmacother; 2021 Oct; 142():111961. PubMed ID: 34329824
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AT101 exerts a synergetic efficacy in gastric cancer patients with 5-FU based treatment through promoting apoptosis and autophagy.
    Wei X; Duan W; Li Y; Zhang S; Xin X; Sun L; Gao M; Li Q; Wang D
    Oncotarget; 2016 Jun; 7(23):34430-41. PubMed ID: 27144437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
    Mani J; Vallo S; Rakel S; Antonietti P; Gessler F; Blaheta R; Bartsch G; Michaelis M; Cinatl J; Haferkamp A; Kögel D
    BMC Cancer; 2015 Apr; 15():224. PubMed ID: 25885284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Organophosphate-pesticides induced survival mechanisms and APE1-mediated Nrf2 regulation in non-small-cell lung cancer cells.
    Thakur S; Sarkar B; Dhiman M; Mantha AK
    J Biochem Mol Toxicol; 2021 Feb; 35(2):e22640. PubMed ID: 33078895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers.
    Song W; Li M; Tang Z; Li Q; Yang Y; Liu H; Duan T; Hong H; Chen X
    Macromol Biosci; 2012 Nov; 12(11):1514-23. PubMed ID: 23070837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.